Caris Life Sciences, Inc. (CAI) |
| 16.64 -0.03 (-0.18%) 05-29 15:09 |
| Open: | 16.78 |
| High: | 17.079 |
| Low: | 16.58 |
| Volume: | 1,118,688 |
| Market Cap: | 4,704(M) |
| PE Ratio: | -6.03 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 20.73 |
| Resistance 1: | 18.23 |
| Pivot price: | 15.65 |
| Support 1: | 14.19 |
| Support 2: | 11.81 |
| 52w High: | 42.5 |
| 52w Low: | 14.19 |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
| EPS | -2.760 |
| Book Value | 2.100 |
| PEG Ratio | 0.00 |
| Gross Profit | 2.212 |
| Profit Margin (%) | 3.75 |
| Operating Margin (%) | 2.44 |
| Return on Assets (ttm) | 9.3 |
| Return on Equity (ttm) | 28.4 |
Wed, 27 May 2026
Caris Life Sciences Inc (CAI) Stock Price Quote Today & Current Price Chart - Capital.com
Tue, 26 May 2026
AI test overturns stage 4 breast cancer diagnosis in Caris case - Stock Titan
Sat, 09 May 2026
Assessing Caris Life Sciences (CAI) Valuation As Shares Trade Below Narrative Fair Value - Yahoo Finance
Fri, 08 May 2026
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization - PR Newswire
Fri, 08 May 2026
JPMorgan Chase & Co. Issues Pessimistic Forecast for Caris Life Sciences (NASDAQ:CAI) Stock Price - MarketBeat
Fri, 08 May 2026
Is It Time To Reconsider Caris Life Sciences (CAI) After 26.5% Year To Date Decline? - simplywall.st
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |